乳腺癌HER2基因扩增与临床病理参数的对比分析OA

Objective To investigate the relationship between HER2 gene amplification status and various clinicopathologi-cal parameters in breast cancer,and to provide a scientific basis for risk prediction of recurrence and metastasis as well as precision tar-geted therapy for breast cancer.Methods A retrospective analysis was conducted on 205 breast cancer patients with human epidermal growth factor receptor 2(HER2)immunohistochemistry(IHC)2+(equivocal)results admitted to Changchun Cancer Hospital from April 2020 to June 2024.Fluorescence in situ hybridization(FISH)was used to detect HER2 gene amplification.The associations be-tween different HER2 amplification statuses and age,tumor diameter,TNM stage,pathological grade,lymph node metastasis,estrogen receptor(ER)/progesterone receptor(PR)expression,and proliferative marker antigen(Ki-67)expression were compared.Fur-thermore,the relationship between HER2 amplification and lymph node metastasis was explored in depth according to different age groups(using 55 years as cut-off),tumor diameters(using 3 cm as cut-off),and Ki-67 expression levels(using 50%as cut-off),with a focus on analyzing the differences in clinicopathological parameters associated with HER2 amplification across different age strati-fications.Results Among the 205 patients,44(21.5%)were positive for HER2 gene amplification.HER2 amplification status was significantly associated with TNM stage,tumor diameter,Ki-67 expression,and ER/PR expression(all P<0.05).Lymph node me-tastasis was significantly associated with age,tumor diameter,and Ki-67 expression(all P<0.05).In patients aged<55 years,the lymph node metastasis rate was significantly higher in the HER2 amplification-positive group than in the negative group(P<0.05).After stratification by tumor diameter and Ki-67 expression,statistically significant differences in TNM stage and lymph node metastasis rate were observed between different age groups(all P<0.05).Conclusion HER2 gene amplification in breast cancer is associated with multiple clinicopathological parameters,and its impact on the risk of lymph node metastasis is age-dependent,with a more pro-nounced risk observed in younger patients.These findings provide a scientific basis and feasibility for improving the precise assessment of recurrence and metastasis risk and for individualized precision medicine in breast cancer.